Generic Version of HIV Drug Recommended for EU
The European Medicines Agency (EMA) has given a positive opinion to a generic medicine, emtricitabine/tenofovir alafenamide, for the treatment of adults and adolescents infected with HIV type 1 (HIV-1).
The EMA's Committee for Medicinal Products for Human Use (CHMP) said that the combination is a generic of the branded medicine Descovy, which has been authorized in the EU since April 21, 2016. The two active substances are antivirals that exert their effects by inhibiting HIV reverse transcriptase through incorporation into the viral DNA, resulting in chain termination.
Studies have demonstrated the satisfactory quality of emtricitabine/tenofovir alafenamide, CHMP said, and its bioequivalence to the reference product Descovy. Like Descovy, emtricitabine/tenofovir alafenamide is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents aged 12 years or older with body weight at least 35 kg, who are infected with HIV-1.
The drug is an oral medication available as 200 mg/25 mg and 200 mg/10 mg film-coated tablets to be taken once daily. The most common side effects include nausea, diarrhea, headache, dizziness, depression, fatigue, insomnia, strange dreams, stomach pain, weight loss, and rash.
Therapy should be initiated by a physician experienced in the management of HIV infection.
Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorization has been granted by the European Commission.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors
Medtronic plc (NYSE:MDT) is one of the 11 best European stocks to invest in. On June 23, the company announced the appointment of Dr. Joon Sup Lee as an independent director to its Board of Directors. The appointment went into effect on June 18, 2025. A healthcare specialist in the laboratory testing an Oncology-related product. Dr. Lee's appointment was a result of Medtronic increasing the size of its Board. The new director will serve on the Board's Science and Technology Committee and the Compensation and Talent Committee. Dr. Lee is currently the CEO of Emory Healthcare, Inc., overseeing Georgia's most comprehensive academic health system. Before joining Emory Healthcare, Dr. Lee was the executive director of the University of Pittsburgh Medical Center's (UPMC) Heart and Vascular Institute from 2018 to 2020. He was also a professor of medicine at the University of Pittsburgh School of Medicine. He held various leadership roles at UPMC, including Director of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory. Medtronic plc (NYSE:MDT) is an Irish-domiciled healthcare technology company. It develops and sells medical devices and therapies for chronic conditions across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its top products include heart devices, spinal implants, surgical tools, insulin pumps, and neuromodulation systems. Medtronic serves over 79 million patients annually in more than 150 countries. While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment
GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment of active lupus nephritis (LN). The approval applies to children aged five years and above. A pharmacist looking at a prescription bottle of gastrointestinal drugs. Benlysta autoinjector is the first-of-its-kind treatment option for at-home administration. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It works by binding to soluble BLyS, which inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. It does not bind B cells directly. The 200 mg/mL autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. Benlysta was the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population. The autoinjector will be available for patients and their caregivers immediately. GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company. It researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders. Its key products include Shingrix (shingles vaccine), Nucala (asthma), and HIV treatments through its ViiV Healthcare joint venture. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the shares of Regulus ceased trading on the NASDAQ exchange, and the company became a fully owned subsidiary of Novartis. lucarista/ The acquisition marks a crucial step in the company's effort to advance the clinical development of a potential first-in-class medicine for autosomal dominant polycystic kidney disease. Regulus Joins Novartis with Farabursen, an investigational next-generation oligonucleotide aiming to reduce the growth of cysts and kidney size. Novartis is a global healthcare company dedicated to discovering and developing innovative medicines that improve and extend people's lives. It also focuses on addressing significant medical challenges, including cancer and rare genetic disorders, by prioritizing research and development, as well as innovative access approaches. Novartis AG (NYSE:NVS) is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines to improve and extend people's lives. It also focuses on using science-based innovation to address significant healthcare challenges. Novartis operates in over 100 countries, with the US accounting for about one-third of its revenue. While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
